Publication of the 2019 Half-Yearly Financial Report
Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]
DIRECT DIRIGEANTS A debate during which Onxeo’s executives present the company’s development strategy, activities, results and prospects. Organized by les […]
Tides Europe 2019 Learn more …. Download management presentation Download poster
Bryan, Garnier & Co European Healthcare Conference Download management presentation
Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics The premier international meeting featuring novel cancer therapeutics. Read more […]
Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]
Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]
Investir Day For more information : www.investirday.fr (French only) Download the management presentation (in French)
DNA Damage Response Therapeutics Summit 2019 Access Management Presentation
Portzamparc MidCap 2019 Access Management Presentation
2019 BIO International Convention Access Management Presentation
CM-CIC Market Solutions Forum Access Management Presentation
Meetings during JP Morgan Conference Access Management Presentation
Biomed Event 2019 Access Management Presentation
Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]
GALIEN MEDSTARTUP 2019 For more information : medstartup.galienfoundation.org
Paris (France), April 5, 2019 – 10 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]
Renewal of the terms of office of Danièle Guyot-Caparros, Jean-Pierre Bizzari and Jean-Pierre Kinet Appointment of Danièle Guyot-Caparros as Chairman […]
Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced […]
The new financing line could represent a total of approximately €9 million over the upcoming 12 months, based on current […]
OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation […]
Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or […]
Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, […]
Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical […]
Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Clinical development of AsiDNA™ continues in phase 1 study DRIIV-1 Activity of AsiDNA™ demonstrated through the marked activation of its […]
Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]
DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in […]